Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo

Cancer Science

Volumn 98, Issue 2, 2007, Pages 219-225

  Oikawa, Tsutomu ^a   Onozawa, Chizuko ^a   Kuranuki, Sachi ^b   Igarashi, Yasuhiro ^c   Sato, Mayumi ^a   Ashino, Hiromi ^a   Shimamura, Mariko ^a   Toi, Masakazu ^d   Kurakata, Shinichi ^e  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b KANAGAWA UNIVERSITY OF HUMAN SERVICES   (Japan)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

14,16 DIPALMITOYL RADICICOL; 22 OXACALCITRIOL; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; MEDROXYPROGESTERONE ACETATE; RADICICOL;

AIR SAC; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENDOTHELIUM CELL; FEMALE; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; TUMOR CELL LINE; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

AIR SACS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE; FATTY ACIDS, MONOUNSATURATED; FEMALE; MACROLIDES; MICE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; SURVIVAL RATE;

EID: 33845641213     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00359.x     Document Type: Article

References (56)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
3. Risau W. Mechanism of angiogenesis. Nature 1997; 386: 671-4.
4. Kuwano M, Uchiumi T, Hayakawa H et.al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94: 9-14.
5. Shibuya M. Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-6.
6. Akiyama S, Furukawa T, Sumizawa T et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 2004; 95: 851-7.
7. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2004; 95: 479-85.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
10. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
11. Oikawa T, Ito H, Ashino H et al. Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur J Pharmacol 1993; 241: 221-7.
12. Oikawa T. Strategies to find novel angiogenesis inhibitors as potential therapeutic agents for cancer. Curr Med Chem 1995; 1: 406-17.
13. Ueda Y, Yamagishi T, Samata K et al. A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. Mol Cancer Ther 2003; 2: 1105-11.
14. Aoki S, Cho SH, Ono M et al. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006; 17: 269-78.
15. Hirata H, Uehara H, Izumi K, Naito S, Kuwano M, Ono M. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 2004; 95: 614-18.
16. Arakawa K, Endo Y, Kimura M et al. Multifunctional anti-angiogenic activity of the cyclic peroxide ANO-2 with antitumor activity. Int J Cancer 2002; 100: 220-7.
17. Uchimiya H, Furukawa T, Okamoto M et al. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-l-ribose. Cancer Res 2002; 62: 2834-9.
18. Watanabe K, Hasegawa Y, Yamashita H et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004; 114: 898-907.
19. Toi M, Bando H, Ramachandran C et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003; 6: 121-8.
20. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
21. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
22. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94: 321-7.
23. Matsumoto G, Namekawa J, Muta M et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11: 1287-93.
24. Minamiguchi K, Kumagai H, Masuda T, Kawada M, Ishizuka M, Takeuchi T. Thiolutin, an inhibitor of HUVEC adhesion to vitronectin, reduces paxillin in HUVECs and suppresses tumor cell-induced angiogenesis. Int J Cancer 2001; 93: 307-16.
25. Kakeya H, Onose R, Koshino H et al. Epoxyquinol A, a highly functionalized pentaketide dimer with antiangiogenic activity isolated from fungal metabolites. J Am Chem Soc 2002; 124: 3496-7.
26. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
27. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
28. Oikawa T, Hirotani K, Shimamura M, Ashino-Fuse H, Iwaguchi T. Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic). J Antibiot (Tokyo) 1989; 42: 1202-4.
29. Oikawa T, Hasegawa M, Shimamura M, Ashino H, Murota S, Morita I. Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor. Biochem Biophys Res Commun 1991; 181: 1070-6.
30. Oikawa T, Sasaki M, Inose M et al. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res 1997; 17: 1881-6.
31. Onozawa C, Shimamura M, Iwasaki S, Oikawa T. Inhibition of angiogenesis by rhizoxin, a microbial metabolite containing two epoxide groups. Jpn J Cancer Res 1997; 88: 1125-9.
32. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T. A highly potent antiangiogenic activity of retinoids. Cancer Lett 1989; 48: 157-62.
33. Oikawa T. Okayasu I. Ashino H, Morita I, Murota S, Shudo K. Three novel synthetic retinoids, Re 80, Am 580 and Am 8 0, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol 1993; 249: 113-16.
34. Oikawa T, Hirotani K, Ogasawara H et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247-50.
35. Oikawa T, Onozawa C, Inose M, Sasaki M. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol Pharm Bull 1995; 18: 1305-7.
36. Oikawa T, Hiragun A, Yoshida Y, Ashino-Fuse H, Tominaga T, Iwaguchi T. Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene and its inhibition by medroxyprogesterone acetate: Possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett 1988; 43: 85-92.
37. Oikawa T, Murakami K, Sano M, Shibata J, Wierzba K, Yamada Y. A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. Jpn J Cancer Res 2001; 92: 1225-34.
38. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
39. Shangari N, Chan TS, O'Brien PJ. Sulfation and glucuronidation of phenols: Implications in coenyzme Q metabolism. Meth Enzymol 2005; 400: 342-59.
40. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719-25.
41. Tanaka NG, Sakamoto N, Inoue K et.al. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res 1989; 49: 6727-30.
42. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-7.
43. Oikawa T, Matsuzawa A, Iwaguchi T. Progression from hormone dependence to autonomy and angiogenesis in mouse mammary tumours. Br J Cancer 1986; 54: 91-6.
44. Oikawa T, Yoshida Y, Shimamura M, Ashino-Fuse H, Iwaguchi T, Tominaga T. Antitumor effect of 22-oxa-1 α,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 1991; 2: 475-80.
45. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
46. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-21.
47. Osada H. Development and application of bioprobes for mammalian cell cycle analyses. Curr Med Chem 2003; 10: 727-32.
48. Kumagai H, Someno T, Dobashi K, Isshiki K, Ishizuka M, Ikeda D. ICM0301s, new angiogenesis inhibitors from Aspergillus sp. F-1491. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2004; 57: 97-103.
49. Oikawa T. Control of angiogenesis by microbial products. In: Fan T-PD, Kohn EC, eds. The New Angiotherapy. Totowa: Humana Press, 2001; 329-55.
50. Soga S, Neckers LM, Schulte TW et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999; 59: 2931-8.
51. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 2001; 92: 1342-51.
52. Soga S, Sharma SV, Shiotsu Y et al. Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother Pharmacol 2001; 48: 435-45.
53. Agatsuma T, Ogawa H, Akasaka K et al. Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities. Bioorg Med Chem 2002; 10: 3445-54.
54. Ikuina Y, Amishiro N, Miyata M et al. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J Med Chem 2003; 46: 2534-41.
55. Takatori T, Koizumi T, Tokui T, Mitsuhashi Y, Shiraishi A, Tsuruo T. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells. Cancer Chemother Pharmacol 1995; 35: 283-90.
56. Kwon HJ, Yoshida M, Fukui Y, Horinouchi S, Beppu T. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res 1992; 52: 6926-30.